BioCentury | Feb 9, 2021
Product Development

KalVista gains on Phase II data for oral HAE treatment

...By Danielle Golovin, Staff Writer KalVista gained $17.89 (114%) to $33.50 on Tuesday after reporting its...
...PGI-C) scale and achieved symptom relief more quickly (p<0.0001) using a composite Visual Analogue Scale (VAS).KalVista...
...Pharmaceuticals Inc. (NASDAQ:BCRX), marking the first approval for an orally administered non-steroidal option to prevent HAE. KalVista...
BioCentury | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

...Lewis previously led the global talent acquisition organization at Biogen Inc. (NASDAQ:BIIB). Protease inhibitor company KalVista...
...NASDAQ:KALV) said CFO Benjamin Palleiko will take on the additional role of CBO. He is KalVista’s...
...CEO Shenda Baker, who remains CSO and a director. BioCentury Staff Axcella Health Inc. Epic Sciences Inc. Imara Inc. Juvenescence Ltd. KalVista...
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...Venrock invested in KalVista Pharmaceuticals Inc. (NASDAQ:KALV) and BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) before backing Attune. KalVista...
...in the lead” for prophylaxis, though it has had clinical issues around gastrointestinal adverse events. KalVista's...
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

...effects as a problem in the product profile or as a negative compared to competitors. KalVista...
...Berndt Modig Patents: None issued Companies and Institutions Mentioned BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. KalVista...
...receptor Complement 1 (C1) esterase KLKB1 - Plasma kallikrein Mary Romeo, Staff Writer BCX7353 Firazyr, icatibant (JE049) KVD818 BioCryst Pharmaceuticals Inc. KalVista...
BioCentury | Oct 13, 2017
Regulation

Expanding the HAE tool kit

...Data are expected by YE18. The company did not respond to requests for an interview. KalVista...
...Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Hereditary Angioedema Association (HAEA), Fairfax City, Va. KalVista...
...maker.” BioCentury (2015) Usdin, S. “HAE’s tightening timeline.” BioCentury (2008) Virginia Li, Staff Writer BCX7353 Haegarda KVD818 subcutaneous C1-INH BioCryst Pharmaceuticals Inc. KalVista...
BioCentury | Oct 13, 2017
Company News

KalVista leaps after Merck deal in DME

...KLKB1) inhibitor, along with future oral plasma kallikrein inhibitors to treat diabetic macular edema (DME). KalVista...
...milestones for each program, as well as tiered royalties. Merck also invested $9.1 million in KalVista...
...KalVista Pharmaceuticals Inc. (NASDAQ:KALV), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Ophthalmic Jennie Walters KVD001 KalVista...
BioCentury | Oct 10, 2017
Company News

KalVista leaps after Merck deal in DME

...kallikrein inhibitor (KLKB1), along with future oral plasma kallikrein inhibitors to treat diabetic macular edema. KalVista...
...milestones for each program, as well as tiered royalties. Merck also invested $9.1 million in KalVista...
...a private placement, giving it a 9.9% stake. The price is a 16% premium to KalVista's...
BioCentury | Jun 27, 2016
Company News

KalVista, Carbylan Therapeutics deal

...Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81%...
...to own an 81% stake in the combined company. The combined company will focus on KalVista’s...
...kallikrein inhibitor , that has completed Phase I testing to treat diabetic macular edema (DME). KalVista...
BioCentury | Jul 27, 2015
Financial News

KalVista completes venture financing

KalVista Pharmaceuticals Ltd. , Salisbury, U.K. Business: Ophthalmic Date completed: 2015-07-22 Type: Venture financing Raised: $33 million Investors: Novo A/S ; SV Life Sciences ; RA Capital Management; Longwood Fund; Venrock WIR Staff Ophthalmic...
BioCentury | Jul 24, 2015
Financial News

KalVista raises $33M in series B

...Longwood Fund and Venrock and existing investors Novo A/S and SV Life Sciences also participated. KalVista...
...angioedema (HAE). RA Capital's Rajeev Shah and Longwood Fund's Rich Aldrich will join KalVista's board. KalVista...
Items per page:
1 - 10 of 21
BioCentury | Feb 9, 2021
Product Development

KalVista gains on Phase II data for oral HAE treatment

...By Danielle Golovin, Staff Writer KalVista gained $17.89 (114%) to $33.50 on Tuesday after reporting its...
...PGI-C) scale and achieved symptom relief more quickly (p<0.0001) using a composite Visual Analogue Scale (VAS).KalVista...
...Pharmaceuticals Inc. (NASDAQ:BCRX), marking the first approval for an orally administered non-steroidal option to prevent HAE. KalVista...
BioCentury | Mar 27, 2019
Company News

Management tracks: Epic, Axcella, KalVista

...Lewis previously led the global talent acquisition organization at Biogen Inc. (NASDAQ:BIIB). Protease inhibitor company KalVista...
...NASDAQ:KALV) said CFO Benjamin Palleiko will take on the additional role of CBO. He is KalVista’s...
...CEO Shenda Baker, who remains CSO and a director. BioCentury Staff Axcella Health Inc. Epic Sciences Inc. Imara Inc. Juvenescence Ltd. KalVista...
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...Venrock invested in KalVista Pharmaceuticals Inc. (NASDAQ:KALV) and BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) before backing Attune. KalVista...
...in the lead” for prophylaxis, though it has had clinical issues around gastrointestinal adverse events. KalVista's...
BioCentury | May 31, 2018
Emerging Company Profile

Oral route for HAE

...effects as a problem in the product profile or as a negative compared to competitors. KalVista...
...Berndt Modig Patents: None issued Companies and Institutions Mentioned BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. KalVista...
...receptor Complement 1 (C1) esterase KLKB1 - Plasma kallikrein Mary Romeo, Staff Writer BCX7353 Firazyr, icatibant (JE049) KVD818 BioCryst Pharmaceuticals Inc. KalVista...
BioCentury | Oct 13, 2017
Regulation

Expanding the HAE tool kit

...Data are expected by YE18. The company did not respond to requests for an interview. KalVista...
...Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Hereditary Angioedema Association (HAEA), Fairfax City, Va. KalVista...
...maker.” BioCentury (2015) Usdin, S. “HAE’s tightening timeline.” BioCentury (2008) Virginia Li, Staff Writer BCX7353 Haegarda KVD818 subcutaneous C1-INH BioCryst Pharmaceuticals Inc. KalVista...
BioCentury | Oct 13, 2017
Company News

KalVista leaps after Merck deal in DME

...KLKB1) inhibitor, along with future oral plasma kallikrein inhibitors to treat diabetic macular edema (DME). KalVista...
...milestones for each program, as well as tiered royalties. Merck also invested $9.1 million in KalVista...
...KalVista Pharmaceuticals Inc. (NASDAQ:KALV), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Ophthalmic Jennie Walters KVD001 KalVista...
BioCentury | Oct 10, 2017
Company News

KalVista leaps after Merck deal in DME

...kallikrein inhibitor (KLKB1), along with future oral plasma kallikrein inhibitors to treat diabetic macular edema. KalVista...
...milestones for each program, as well as tiered royalties. Merck also invested $9.1 million in KalVista...
...a private placement, giving it a 9.9% stake. The price is a 16% premium to KalVista's...
BioCentury | Jun 27, 2016
Company News

KalVista, Carbylan Therapeutics deal

...Carbylan will merge with KalVista in a stock deal, with KalVista expected to own an 81%...
...to own an 81% stake in the combined company. The combined company will focus on KalVista’s...
...kallikrein inhibitor , that has completed Phase I testing to treat diabetic macular edema (DME). KalVista...
BioCentury | Jul 27, 2015
Financial News

KalVista completes venture financing

KalVista Pharmaceuticals Ltd. , Salisbury, U.K. Business: Ophthalmic Date completed: 2015-07-22 Type: Venture financing Raised: $33 million Investors: Novo A/S ; SV Life Sciences ; RA Capital Management; Longwood Fund; Venrock WIR Staff Ophthalmic...
BioCentury | Jul 24, 2015
Financial News

KalVista raises $33M in series B

...Longwood Fund and Venrock and existing investors Novo A/S and SV Life Sciences also participated. KalVista...
...angioedema (HAE). RA Capital's Rajeev Shah and Longwood Fund's Rich Aldrich will join KalVista's board. KalVista...
Items per page:
1 - 10 of 21